Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cardiovascular Syst (CSII)

Cardiovascular Syst (CSII)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cardiovascular Syst 1225 OLD HWY 8 NW ST. PAUL MN 55112 USA

P: 651-259-1600 F: 612-677-3355

Description:

Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360' Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360' removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.

Key Statistics

Overview:

Market Capitalization, $K 1,566,684
Shares Outstanding, K 40,192
Annual Sales, $ 236,550 K
Annual Net Income, $ -27,240 K
Last Quarter Sales, $ 64,170 K
Last Quarter Net Income, $ -60 K
60-Month Beta 0.83
% of Insider Shareholders 3.00%
% of Institutional Shareholders 91.95%
Float, K 38,986
% Float 97.00%

Growth:

1-Year Return -1.81%
3-Year Return 73.09%
5-Year Return 164.81%
5-Year Revenue Growth 30.30%
5-Year Earnings Growth 24.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 02/03/21
Next Earnings Date 05/06/21
Earnings Per Share ttm -0.56
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year 100.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 02/26/09

CSII Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -579.09
Price/Earnings to Growth N/A
Return-on-Equity % -8.46%
Return-on-Assets % -6.46%
Profit Margin % -11.52
Net Margin % -14.12
Debt/Equity 0.08
Price/Sales 6.49
Price/Cash Flow N/A
Price/Book 5.61
Book Value/Share 6.81
Interest Coverage -12.71
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar